CP-199,330 (3) and CP-199,331 (4) are cysLT1 receptor antagonists that are equipotent to marketed cysLT1 receptor antagonists zafirlukast and pranlukast, show good pharmacokinetics in rats and monkeys, and are devoid of liver toxicity in monkeys as seen in CP-85,958 (1).

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(99)00461-8DOI Listing

Publication Analysis

Top Keywords

receptor antagonists
12
cp-199330 cp-199331
8
devoid liver
8
liver toxicity
8
cyslt1 receptor
8
discovery cp-199330
4
cp-199331 potent
4
potent orally
4
orally efficacious
4
efficacious cysteinyl
4

Similar Publications

Behavioral Profiling in Zebrafish Identifies Insecticide-Related Compounds.

J Agric Food Chem

January 2025

Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.

Pesticides, including insecticides, are indispensable for large-scale agriculture. Modulating chloride ion channels has proven highly successful as a mode of action (MoA) for insect management. Identifying new ligands for these channels affords opportunities for the potential development of new insecticide products.

View Article and Find Full Text PDF

Tigilanol tiglate (EBC-46) is a selective modulator of protein kinase C (PKC) isoforms that is Food and Drug Administration (FDA) approved for the treatment of mast cell tumors in canines with up to an 88% cure rate. Recently, it has been FDA approved for the treatment of soft tissue sarcomas in humans. The role of EBC-46 and, especially, its analogs in efforts to eradicate HIV, treat neurological and cardiovascular disorders, or enhance antigen density in antigen-targeted chimeric antigen receptor-T cell and chimeric antigen receptor-natural killer cell immunotherapies has not been reported.

View Article and Find Full Text PDF

Intra-abdominal sepsis is a life-threatening complex syndrome caused by microbes in the gut microbiota invading the peritoneal cavity. It is one of the major complications of intra-abdominal surgery. To date, only supportive therapies are available.

View Article and Find Full Text PDF

HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC.

Cancer Chemother Pharmacol

January 2025

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Background: The expression of anti-programmed cell death ligand-1 (PD-L1) in tumors is widely used as a biomarker to predict the therapeutic efficacy of anti-programmed cell death-1(PD-1)/PD-L1 antibodies. However, the predictive accuracy of this method is limited. High-mobility group box 1 (HMGB1) is known to modulate cancer immunity.

View Article and Find Full Text PDF

Epidemiological studies suggest an increased risk of colorectal cancer (CRC) aggravation in patients with chronic kidney disease (CKD). Our previous study demonstrated that indoxyl sulfate, a uremic toxin whose concentration increases with CKD progression, exacerbates CRC through activation of the AhR and Akt pathways. Consequently, indoxyl sulfate has been proposed to be a significant link between CKD progression and CRC aggravation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!